MTOR and adenocarcinoma: In recent years, immunosuppressive medication modification including CNI-free regimens, substitution by mammalian target of rapamycin inhibitors or reduction in dosage of immunosuppression has been utilized as a treatment after cancer diagnosis in some transplant patients.[34,35] It has been speculated that the use of rapamycin, instead of CNI might reduce the recurrence of cancer in transplant patients.[36] In a case of adenocarcinoma in the stage of III B, as in our patient, switching immunosuppression regimen from cyclosporin to rapamycin might be helpful for his survival after surgery.